Is GRP78/BiP a potential salivary biomarker in patients with rheumatoid arthritis?

Proteomics - Clinical Applications

Volumn 4, Issue 3, 2010, Pages 315-324

  Giusti, Laura ^a   Baldini, Chiara ^a   Ciregia, Federica ^a   Giannaccini, Gino ^a   Giacomelli, Camillo ^a   de Feo, Francesca ^a   Sedie, Andrea Delle ^a   Riente, Lucrezia ^a   Lucacchini, Antonio ^a   Bazzichi, Laura ^a   Bombardieri, Stefano ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

78 kDa glucose regulated protein precursor; Biomarkers; Rheumatoid arthritis; Whole saliva

Indexed keywords

APOLIPOPROTEIN A1; BIOLOGICAL MARKER; CALGRANULIN A; CALGRANULIN B; CHAPERONE; CYCLOSPORIN; EPIDERMAL FATTY ACID BINDING PROTEIN; FATTY ACID BINDING PROTEIN; GLUCOSE REGULATED PROTEIN 78; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; PEROXIREDOXIN 5; PHOSPHOGLUCONATE DEHYDROGENASE; PROTEIN 14 3 3; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ALGORITHM; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; SALIVA ANALYSIS; SALIVA LEVEL; SEROLOGY; TWO DIMENSIONAL ELECTROPHORESIS; WESTERN BLOTTING;

ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; FEMALE; GENE EXPRESSION REGULATION; HEAT-SHOCK PROTEINS; HUMANS; MALE; MIDDLE AGED; PROTEOMICS; REPRODUCIBILITY OF RESULTS; SALIVA; SALIVARY PROTEINS AND PEPTIDES; SEROLOGIC TESTS;

EID: 77951732049     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.200900082     Document Type: Article

References (60)

1. Scott, D.L., Steer, S., The course of established rheumatoid arthritis. Best Pract. Res. Clin. Rheumatol. 2007, 21, 943-967.
2. van der Leeden, M., Steultjens, M., Dekker, J.H., Prins, A.P., Dekker, J., The relationship of disease duration to foot function, pain and disability in rheumatoid arthritis patients with foot complaints. Clin. Exp. Rheumatol. 2007, 25, 275-280.
3. Sokka, T., Haugeberg, G., Pincus, T., Assessment of quality of rheumatoid arthritis care requires joint count and/or patient questionnaire data not found in a usual medical record: examples from studies of premature mortality, changes in clinical status between 1985 and 2000, and a QUEST-RA global perspective. Clin. Exp. Rheumatol. 2007, 25, 86-97.
4. Savage, C., St Clair, E.W., New therapeutics in rheumatoid arthritis. Rheum. Dis. Clin. North Am. 2006, 32, 57-74.
5. Youinou, P., Jamin, C., Saraux, A., B-cell: a logical target for treatment of rheumatoid arthritis. Clin. Exp. Rheumatol. 2007, 25, 318-328.
6. Rozelle, A.L., Genovese, M.C., Efficacy results from pivotal clinical trials with abatacept. Clin. Exp. Rheumatol. 2007, 25, S30-S34.
7. Dasuri, K., Antonovici, M., Chen, K., Wong, K. et al., The synovial proteome: analysis of fibroblast-like synoviocytes. Arthritis Res. Ther. 2004, 6, R161-R168.
8. Uchida, T., Fukawa, A., Uchida, M., Fujita, K., Saito, K., Application of a novel protein biochip technology for detection and identification of rheumatoid arthritis biomarkers in synovial fluid. J. Proteome Res. 2002, 1, 495-499.
9. Liao, H., Wu, J., Kuhn, E., Chin, W. et al., Use of mass spectrometry to identify protein biomarkers of disease severity in the synovial fluid and serum of patients with rheumatoid arthritis. Arthritis Rheum. 2004, 50, 3792-3803.
10. Kim, C.W., Cho, E.H., Lee, Y.J., Kim, Y.H. et al., Diseasespecific proteins from rheumatoid arthritis patients. J. Korean Med. Sci. 2006, 21, 478-484.
11. de Seny, D., Fillet, M., Meuwis, M.A., Geurts, P. et al., Discovery of new rheumatoid arthritis biomarkers using the surface-enhanced laser desorption/ionization time-of-flight mass spectrometry ProteinChip approach. Arthritis Rheum. 2005, 52, 3801-3812.
12. Sekigawa, I., Yanagida, M., Iwabuchi, K., Kaneda, K. et al., Protein biomarker analysis by mass spectrometry in patients with rheumatoid arthritis receiving anti-tumor necrosis factor-alpha antibody therapy. Clin. Exp. Rheumatol. 2008, 26, 261-267.
13. de Seny, D., Fillet, M., Ribbens, C., Maré e, R. et al., Monomeric calgranulins measured by SELDI-TOF mass spectrometry and calprotectin measured by ELISA as biomarkers in arthritis. Clin. Chem. 2008, 54, 1066-1075.
14. Miyamae, T., Malehorn, D.E., Lemster, B., Mori, M. et al., Serum protein profile in systemic-onset juvenile idiopathic arthritis differentiates response versus nonresponse to therapy. Arthritis Res. Ther. 2005, 7, R746-R755.
15. Gibson, D.S., Blelock, S., Brockbank, S., Curry, J. et al., Proteomic analysis of recurrent joint inflammation in juvenile idiopathic arthritis. J. Proteome Res. 2006, 5, 1988-1995.
16. Xiang, Y., Sekine, T., Nakamura, H., Imajoh-Ohmi, S. et al., Proteomic surveillance of autoimmunity in osteoarthritis: identification of triosephosphate isomerase as an autoantigen in patients with osteoarthritis. Arthritis Rheum. 2004, 50, 1511-1521.
17. Gobezie, R., Kho, A., Krastins, B., Sarracino, D.A. et al., High abundance synovial fluid proteome: distinct profiles in health and osteoarthritis. Arthritis Res. Ther. 2007, 9, R36.
18. Liu, J., Zhu, P., Peng, J., Li, K. et al., Identification of diseaseassociated proteins by proteomic approach in ankylosing spondylitis. Biochem. Biophys. Res. Commun. 2007, 357, 531-536.
19. Bresnihan, B., Synovial biomarkers in the spondylarthropathies. Curr. Opin. Rheumatol. 2006, 18, 359-363.
20. Ryu, O. H ., Atkinson, J.C., Hoehn, G.T., Illei, G.G., Hart, T.C., Identification of parotid salivary biomarkers in Sjö gren's syndrome by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry and twodimensional difference gel electrophoresis. Rheumatology (Oxford) 2006, 45, 1077-1086.
21. Giusti, L., Baldini, C., Bazzichi, L., Ciregia, F. et al., Proteome analysis of whole saliva: a new tool for rheumatic diseases - the example of Sjö gren's syndrome. Proteomics 2007, 7, 1634-1643.
22. Hu, S., Wang, J., Meijer, J., Ieong, S. et al., Salivary proteomic and genomic biomarkers for primary Sjö gren's syndrome. Arthritis Rheum. 2007, 56, 3588-3600.
23. Giusti, L., Bazzichi, L., Baldini, C., Ciregia, F. et al., Specific proteins identified in human whole saliva from systemic sclerosis patients. J. Rheumatol. 2007, 34, 2063-2069.
24. Peluso, G., De Santis, M., Inzitari, R., Fanali, C. et al., Proteomic study of salivary peptides and proteins in patients with Sjö gren's syndrome before and after pilocarpine treatment. Arthritis Rheum. 2007, 56, 2216-2222.
25. Baldini, C., Giusti, L., Bazzichi, L., Ciregia, F. et al., Association of psoriasin (S100A7) with clinical manifestations of systemic sclerosis: is its presence in whole saliva a potential predictor of pulmonary involvement? J. Rheumatol. 2008; 35, 1820-1824.
26. Arnett, F.C., Edworthy, S.M., Bloch, D.A., McShane, D.J. et al., The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988, 31, 315-324.
27. Dougados, M., Aletaha, D., van Riel, P., Disease activity measures for rheumatoid arthritis. Clin. Exp. Rheumatol. 2007, 25, S22-S29.
28. Hochstrasser, D.F., Patchornik, A., Merril, C.R., Development of polyacrylamide gels that improve the separation of proteins and their detection by silver staining. Anal. Biochem. 1988, 173, 412-423.
29. Chevallet, M., Luche, S., Rabilloud, T., Silver staining of proteins in polyacrylamide gels. Nat. Protoc. 2006, 1, 1852-1858.
30. Candiano, G., Bruschi, M., Musante, L., Cantucci, L. et al., Blue silver: a very sensitive colloidal Coomassie G-250 staining for proteome analysis. Electrophoresis 2004, 25, 1327-1333.
31. Bläss, S., Haferkamp, C., Specker, C., Schwochau, M. et al., Rheumatoid arthritis: autoreactive T cells recognising a novel 68k autoantigen. Ann. Rheum. Dis. 1997, 56, 317-322.
32. Bläss, S., Specker, C., Lakomek, H.J., Schneider, E.M., Schwochau, M., Novel 68 kDa autoantigen detected by rheumatoid arthritis specific antibodies. Ann. Rheum. Dis. 1995, 54, 355-360.
33. Haas, I.G., BiP (GRP78), an essential hsp70 resident protein in the endoplasmic reticulum. Experientia 1994, 50, 1012-1020.
34. Gething, M.J., Role and regulation of the ER chaperone BiP. Semin. Cell. Dev. Biol. 1999, 10, 465-472.
35. Bläss, S., Union, A., Raymackers, J., Schumann, F. et al., The stress protein BiP is overexpressed and is a major B and T cell target in rheumatoid arthritis. Arthritis Rheum. 2001, 44, 761-771.
36. Corrigall, V.M., Bodman-Smith, M.D., Fife, M.S., Canas, B. et al., The human endoplasmic reticulum molecular chaperone BiP is an autoantigen for rheumatoid arthritis and prevents the induction of experimental arthritis. J. Immunol. 2001, 166, 1492-1498.
37. Corrigall, V.M., Bodman-Smith, M.D., Brunst, M., Cornell, H., Panayi, G.S., Inhibition of antigen-presenting cell function and stimulation of human peripheral blood mononuclear cells to express an antiinflammatory cytokine profile by the stress protein BiP: relevance to the treatment of inflammatory arthritis. Arthritis Rheum. 2004, 50, 1164-1171.
38. Bodman-Smith, M.D., Corrigall, V.M., Berglin, E., Cornell, H.R. et al., Antibody response to the human stress protein BiP in rheumatoid arthritis. Rheumatology (Oxford) 2004, 43, 1283-1287.
39. Panayi, G.S., Corrigall, V.M., Pitzalis, C., Pathogenesis of rheumatoid arthritis. The role of T cells and other beasts. Rheum. Dis. Clin. North Am. 2001, 27, 317-334.
40. Panayi, G.S., Corrigall, V.M., BiP: a new biologic immunomodulator for the treatment of rheumatoid arthritis. Autoimmun. Rev. 2004, 3, S16-S17.
41. Panayi, G.S., Corrigall, V.M., BiP regulates autoimmune inflammation and tissue damage. Autoimmun. Rev. 2006, 5, 140-142.
42. Panayi, G.S., Corrigall, V.M., BiP, an anti-inflammatory ER protein, is a potential new therapy for the treatment of rheumatoid arthritis. Novartis Found. Symp. 2008, 291, 212-224.
43. Brownlie, R.J., Myers, L.K., Wooley, P.H., Corrigall, V.M. et al., Treatment of murine collagen-induced arthritis by the stress protein BiP via interleukin-4-producing regulatory T cells: a novel function for an ancient protein. Arthritis Rheum. 2006, 54, 854-863.
44. Bodman-Smith, M.D., Corrigall, V.M., Kemeny, D.M., Panayi, G.S., BiP, a putative autoantigen in rheumatoid arthritis, stimulates IL-10-producing CD8-positive T cells from normal individuals. Rheumatology (Oxford) 2003, 42, 637-644.
45. Bartosik-Psujek, H., Stelmasiak, Z., Biochemical markers of damage of the central nervous system in multiple sclerosis. Ann. Univ. Mariae Curie Sklodowska 2001, 56, 389-392.
46. Aitken, A., 14-3-3 proteins: a historic overview. Semin. Cancer Biol. 2006, 16, 162-172.
47. Aitken, A., 14-3-3 and its possible role in co-ordinating multiple signalling pathways. Trends Cell. Biol. 1996, 6, 341-347.
48. Kilani, R.T., Maksymowych, W.P., Aitken, A., Boire, G., Detection of high levels of 2 specific isoforms of 14-3-3 proteins in synovial fluid from patients with joint inflammation. J. Rheumatol. 2007, 34, 1650-1657.
49. Bresnihan, B., Gogarty, M., Fitzgerald, O., Dayer, J.M., Burger, D., Apolipoprotein A-I infiltration in rheumatoid arthritis synovial tissue: a control mechanism of cytokine production? Arthritis Res. Ther. 2004, 6, R563-R566.
50. Hyka, N., Dayer, J.M., Modoux, C., Kohno, T. et al., Apolipoprotein A-I inhibits the production of interleukin-1beta and tumor necrosis factor-alpha by blocking contact-mediated activation of monocytes by T lymphocytes. Blood 2001, 97, 2381-2389.
51. Hagens, G., Masouyé, I., Augsburger, E., Hotz, R., Calciumbinding protein S100A7 and epidermal-type fatty acidbinding protein are associated in the cytosol of human keratinocytes. Biochem. J. 1999, 339, 419-427.
52. Yeung, D.C., Wang, Y., Xu, A., Cheung, S.C. et al., Epidermal fatty-acid-binding protein: a new circulating biomarker associated with cardio-metabolic risk factors and carotid atherosclerosis. Eur. Heart J. 2008, 29, 2156-2163.
53. De Rycke, L., Baeten, D., Foell, D., Kruithof, E. et al., Differential expression and response to anti-TNF alpha treatment of infiltrating versus resident tissue macrophage subsets in autoimmune arthritis. J. Pathol. 2005, 206, 17-27.
54. Flohé, L., Budde, H., Hofmann, B., Peroxiredoxins in antioxidant defense and redox regulation. Biofactors 2003, 19, 3-10.
55. Hofmann, B., Hecht, H.J., Flohé, L., Peroxiredoxins. Biol. Chem. 2002, 383, 347-364.
56. Wood, Z.A., Schröder, E., Robin Harris, J., Poole, L.B., Structure, mechanism and regulation of peroxiredoxins. Trends Biochem. Sci. 2003, 28, 32-40.
57. Karasawa, R., Ozaki, S., Nishioka, K., Kato, T., Autoantibodies to peroxiredoxin I and IV in patients with systemic autoimmune diseases. Microbiol. Immunol. 2005, 49, 57-65.
58. Kalpakcioglu, B., Senel, K., The interrelation of glutathione reductase, catalase, glutathione peroxidase, superoxide dismutase, and glucose-6-phosphate in the pathogenesis of rheumatoid arthritis. Clin. Rheumatol. 2008, 27, 141-145.
59. Afonso, V., Champy, R., Mitrovic, D., Collin, P., Lomri, A., Reactive oxygen species and superoxide dismutases: role in joint diseases. Joint Bone Spine 2007, 74, 324-329.
60. Hitchon, C.A., El-Gabalawy, H.S., Oxidation in rheumatoid arthritis. Arthritis Res. Ther. 2004, 6, 265-278.